Medication info
Actimmet Tablet 15/850mg

Actimmet Tablet 15/850mg

Prescription medicationTablet
Ingredient · strength
Metformin Hydrochloride›850mg / 1 tabletPioglitazone Hydrochloride›16.53mg / 1 tablet
Manufacturer / importer
Kujoo Pharmaceutical Co., Ltd.
Appearance
White to grayish-white oblong film-coated tablet
Packaging
30 tablets (10 tablets/PTP * 3)
Approval status
Active

MFDS item code 201804095 · Approved 2018.10.16

Summary

Main use
Improvement of glycemic control in patients with type 2 diabetes mellitus
Who uses it
Adults
Adult dosage
For the treatment of patients with type 2 diabetes mellitus, the dose of this drug should be individualized based on efficacy and tolerability, without exceeding the maximum dose of each component: pioglitazone 30mg and metformin 2500mg. The initial dose of this drug should be based on the patient's current treatment regimen. 1. Patients whose blood glucose is not adequately controlled with metformin or pioglitazone monotherapy: The dose should be based on the current dose of metformin or pioglitazone. Start with 1 tablet of this drug daily and gradually adjust the dose after assessing the adequacy of the treatment response. 2. Patients switching from combination therapy with pioglitazone and metformin: Patients switching from combination therapy with pioglitazone and metformin to this drug may start at their existing doses of pioglitazone and metformin. No studies have been conducted to evaluate the safety and efficacy of switching from another oral antihyperglycemic drug to this drug. Any change in treatment for type 2 diabetes mellitus may alter glycemic control; therefore, caution should be exercised and appropriate monitoring should be performed. 3. Patients with renal impairment: All dosage adjustments should be based on careful assessment of renal function. In general, older adults and debilitated or malnourished patients should not be titrated up to the maximum dose of this drug. After administering this drug to a patient, or when increasing the dose, carefully monitor for adverse reactions associated with fluid retention. This drug should generally be administered in divided doses with meals to reduce gastrointestinal adverse reactions caused by metformin. Allow sufficient time to assess the adequacy of the treatment response. Ideally, response to treatment should be assessed using glycated hemoglobin (HbA1C), which is a better indicator of long-term glycemic control than fasting plasma glucose (FPG). HbA1c reflects blood glucose levels over the preceding 2 - 3 months. In clinical use of this drug, if glycemic control measured by FPG has not worsened, administration for an appropriate period (8-12 weeks) is recommended to assess changes in HbA1C.

Ingredients

Manufacturer
Kujoo Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of glycemic control in patients with type 2 diabetes mellitus

View approved original text

This medication is used to help improve blood sugar control more effectively when patients with type 2 diabetes follow dietary and exercise therapy. It provides stable blood sugar management through a favorable combination of pioglitazone and metformin. Therefore, this medication is used to improve blood sugar levels alongside lifestyle modifications.

Dosage and Administration

Adult dosage

For the treatment of patients with type 2 diabetes mellitus, the dose of this drug should be individualized based on efficacy and tolerability, without exceeding the maximum dose of each component: pioglitazone 30mg and metformin 2500mg. The initial dose of this drug should be based on the patient's current treatment regimen. 1. Patients whose blood glucose is not adequately controlled with metformin or pioglitazone monotherapy: The dose should be based on the current dose of metformin or pioglitazone. Start with 1 tablet of this drug daily and gradually adjust the dose after assessing the adequacy of the treatment response. 2. Patients switching from combination therapy with pioglitazone and metformin: Patients switching from combination therapy with pioglitazone and metformin to this drug may start at their existing doses of pioglitazone and metformin. No studies have been conducted to evaluate the safety and efficacy of switching from another oral antihyperglycemic drug to this drug. Any change in treatment for type 2 diabetes mellitus may alter glycemic control; therefore, caution should be exercised and appropriate monitoring should be performed. 3. Patients with renal impairment: All dosage adjustments should be based on careful assessment of renal function. In general, older adults and debilitated or malnourished patients should not be titrated up to the maximum dose of this drug. After administering this drug to a patient, or when increasing the dose, carefully monitor for adverse reactions associated with fluid retention. This drug should generally be administered in divided doses with meals to reduce gastrointestinal adverse reactions caused by metformin. Allow sufficient time to assess the adequacy of the treatment response. Ideally, response to treatment should be assessed using glycated hemoglobin (HbA1C), which is a better indicator of long-term glycemic control than fasting plasma glucose (FPG). HbA1c reflects blood glucose levels over the preceding 2 - 3 months. In clinical use of this drug, if glycemic control measured by FPG has not worsened, administration for an appropriate period (8-12 weeks) is recommended to assess changes in HbA1C.

Precautions

This medication can cause severe lactic acidosis and hypoglycemia, thus caution is required, especially in patients with impaired renal function or those with heart or lung conditions or sepsis. Lactic acidosis is rare but a very dangerous condition that can occur due to the accumulation of this medication in the body and can be fatal. It is advisable not to administer this medication to patients with liver dysfunction, and excessive acute or chronic alcohol intake should also be avoided. Patients with heart failure or severe cardiac conditions should not use this medication, and if signs of heart failure occur, immediate consultation with medical personnel is necessary. Patients with active bladder cancer or a history of bladder cancer should carefully consider the risks and benefits before using this medication. Women who are pregnant or breastfeeding should not take this medication, and safety in pediatric patients has not been established. Elderly patients may have reduced kidney function, so it is important to adjust the dosage and regularly monitor kidney function. During the course of taking this medication, blood sugar levels, kidney function, liver function, and hematological parameters should be routinely checked, and any abnormal symptoms should be reported to a physician immediately. Additionally, the administration of this medication should be temporarily discontinued before and after surgery or tests using iodine contrast agents, and it should be re-administered only after confirming renal function. This medication may interact with other drugs, so it is crucial to inform the medical staff of any other medications being taken. There is a risk of hypoglycemia due to irregular meals, excessive exercise, or the combination with other hypoglycemic agents, necessitating caution. In case of overdose, appropriate supportive therapy and possibly hemodialysis may be needed; hence, dosages must be strictly adhered to.

Side effects

  • Lactic acidosis
  • hypoglycemia
  • fatigue
  • myalgia
  • dyspnea
  • asthenia
  • abdominal pain
  • hypothermia
  • hypotension
  • resistant bradyarrhythmia
Show 34 more
  • upper respiratory infection
  • diarrhea
  • complex edema
  • peripheral edema
  • headache
  • nausea
  • urinary tract infection
  • sinusitis
  • dizziness
  • lower extremity edema
  • weight gain
  • myalgia
  • dental disorders
  • worsening of diabetes
  • pharyngitis
  • anemia
  • reduced vision
  • diabetic macular edema
  • liver failure
  • congestive heart failure
  • edema
  • weight gain
  • dyspepsia
  • insomnia
  • dry mouth
  • constipation
  • abdominal distension
  • gastroesophageal reflux disease
  • intestinal air retention
  • increased serum creatinine
  • increased blood urea
  • fracture
  • blood sugar abnormalities
  • gastroenteritis

Not everyone experiences these, and they can vary from person to person.

Storage

This medication may be sensitive to air or moisture, so it should be stored in a tightly closed container. The storage temperature should be maintained at room temperature between 1°C and 30°C. Proper storage will help maintain the medication's effectiveness for a longer duration.

Appearance and packaging

Appearance

White to grayish-white oblong film-coated tablet

Package unit

30 tablets (10 tablets/PTP * 3)

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.